If You Invested in ASYMCHEM LABORATORIES TIANJIN (ASLTY)

Asymchem Laboratories (Tianjin) Co., Ltd., represented by ASLTY as an ADR reference, operates as a contract development and manufacturing organization serving pharmaceutical and biotechnology companies. The company provides development and manufacturing services that support drug programs from early research and process work through clinical and commercial supply. Its disclosed service areas include chemical process development, pre-formulation studies, formulation development, drug substance and drug product development, non-GMP production, GMP active pharmaceutical ingredient production, and manufacturing support for small molecules, peptides, oligonucleotides, and biologics.

Asymchem's business model is based on CDMO services for client-sponsored drug development programs. The company supports pharmaceutical and biotech customers by developing manufacturing processes, preparing clinical supply, and operating manufacturing capacity for drug substance and drug product needs. Reported client work has included process development and GMP bulk drug substance production for an oral small-molecule oncology candidate, illustrating the company's role as a manufacturing and development partner rather than a proprietary drug developer in that engagement.

The company's U.S. presence includes Asymchem Boston in Woburn, Massachusetts, a wholly owned subsidiary focused on early-stage research and development services. The Boston site provides chemical process development, analytical and process laboratory capabilities, pre-formulation and formulation work, and support for small molecules, peptides, and oligonucleotides. It also functions as a liaison between biotech clients and Asymchem's China-based manufacturing sites, connecting early development work with larger-scale manufacturing resources.

Asymchem's biologics capabilities are disclosed through AsymBio, a subsidiary of Asymchem Group. AsymBio operates a Shanghai-based network that includes the Zhangjiang Science & Technology Center, the Jinshan Site, and the Fengxian commercial manufacturing site. This structure is described as a dual-site and one-center model designed to integrate early research and process development, clinical pilot-scale production, and commercial manufacturing for biologics programs.

AsymBio's disclosed manufacturing platform includes single-use bioreactors for antibody drug substance, conjugation reactors for conjugate drug substance, automated filling equipment, lyophilization capacity, and isolator filling systems. The company also identifies integrated payload-linker capabilities, supporting work in biologics and conjugated drug formats. Together, these assets place Asymchem within the outsourced pharmaceutical services market, where customers use CDMO partners for specialized development, manufacturing, and scale-up functions across drug modalities.